General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials

Keyphrases

• Osteoarthritis 100%
• Tolerability 100%
• Randomized Placebo-controlled Trial 100%
• Pooled Analysis 100%
• Tanezumab 100%
• General Safety 100%
• Placebo 81%
• Treatment-related Adverse Events 63%
• Safety Events 27%
• Advanced Osteoarthritis 18%
• Sympathetic Neuropathy 18%
• High Dose 9%
• Adjusted Rates 9%
• In(III) 9%
• Safety Profile 9%
• Adverse Event Rates 9%
• Treatment Duration 9%
• Treatment Discontinuation 9%
• Bradycardia 9%
• Paresthesia 9%
• Discontinuation Rate 9%
• Orthostatic Hypotension 9%
• Hypoesthesia 9%
• Osteonecrosis 9%
• Pathologic Fracture 9%
• Expert Committees 9%
• Total Joint Replacement 9%
• Hip or Knee Osteoarthritis 9%
• Replacement Rate 9%
• Composite Joint 9%
• Subchondral Insufficiency Fracture 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Tolerability 100%
• Osteoarthritis 100%
• Placebo 100%
• Tanezumab 100%
• Adverse Event 63%
• Neuropathy 18%
• Knee Osteoarthritis 9%
• Orthostatic Hypotension 9%
• Hip Osteoarthritis 9%
• Bone Necrosis 9%
• Pathologic Fracture 9%
• Paresthesia 9%
• Hypoesthesia 9%